Immunogenicity of the tuberculosis vaccine MVA85A is reduced by coadministration with EPI vaccines in a randomized controlled trial in Gambian infants.

Immunogenicity of the tuberculosis vaccine MVA85A is reduced by coadministration with EPI vaccines in a randomized controlled trial in Gambian infants.

عرض إصدارات أخرى (1)

New tuberculosis vaccines are urgently needed to curtail the current epidemic. MVA85A is a subunit vaccine that could enhance immunity from BCG vaccination. To determine MVA85A safety and immunogenicity as well as interactions with other routine vaccines administered in infancy, we randomized health...

وصف كامل

التفاصيل البيبلوغرافية
المؤلفون الرئيسيون:	Ota, M, Odutola, A, Owiafe, P, Donkor, S, Owolabi, O, Brittain, N, Williams, N, Rowland-Jones, S, Hill, A, Adegbola, R, McShane, H
التنسيق:	Journal article
اللغة:	English
منشور في:	2011

مواد مشابهة

Immunogenicity of the Tuberculosis Vaccine MVA85A Is Reduced by Coadministration with EPI Vaccines in a Randomized Controlled Trial in Gambian Infants
حسب: Ota, M, وآخرون
منشور في: (2011)

A new TB vaccine, MVA85A, induces durable antigen-specific responses 14 months after vaccination in African infants
حسب: Odutola, A, وآخرون
منشور في: (2012)

A new TB vaccine, MVA85A, induces durable antigen-specific responses 14 months after vaccination in African infants.
حسب: Odutola, A, وآخرون
منشور في: (2012)

Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa.
حسب: Brookes, R, وآخرون
منشور في: (2008)

Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa.
حسب: Roger H Brookes, وآخرون
منشور في: (2008-08-01)

Correction: Safety and Immunogenicity of the Candidate Tuberculosis Vaccine MVA85A in West Africa.
حسب: Roger H. Brookes, وآخرون
منشور في: (2011-01-01)

A review of the tolerability of the candidate TB vaccine, MVA85A compared with BCG and Yellow Fever vaccines, and correlation between MVA85A vaccine reactogenicity and cellular immunogenicity
حسب: Rowland, R, وآخرون
منشور في: (2012)

Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults
حسب: Pathan, A, وآخرون
منشور في: (2012)

Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults.
حسب: Pathan, A, وآخرون
منشور في: (2012)

Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery
حسب: Meyer, J, وآخرون
منشور في: (2013)

Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85A.
حسب: Whelan, K, وآخرون
منشور في: (2009)

Differential cytokine levels in adults induced by a Novel candidate TB boost vaccine, MVA85A-according to previous BCG vaccination status
حسب: Owiafe, P, وآخرون
منشور في: (2012)

Early clinical trials with a new tuberculosis vaccine, MVA85A, in tuberculosis-endemic countries: issues in study design.
حسب: Ibanga, H, وآخرون
منشور في: (2006)

Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery.
حسب: Meyer, J, وآخرون
منشور في: (2013)

Safety and immunogenicity of the malaria candidate vaccines FP9 CS and MVA CS in adult Gambian men.
حسب: Imoukhuede, E, وآخرون
منشور في: (2006)

Evaluation of the safety and immunogenicity of a candidate tuberculosis vaccine, MVA85A, delivered by aerosol to the lungs of macaques.
حسب: White, A, وآخرون
منشور في: (2013)

Comparison of the safety and immunogenicity of a candidate TB vaccine, MVA85A, given by the intramuscular or intradermal route in BCG-vaccinated adults
حسب: Harris, S, وآخرون
منشور في: (2011)

Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals.
حسب: Sander, C, وآخرون
منشور في: (2009)

Correction: Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A.
حسب: Kathryn T. Whelan, وآخرون
منشور في: (2011-01-01)

Safety and immunogenicity of malaria vectored vaccines given with routine EPI vaccines in Gambian infants and neonates: a randomized controlled trial
حسب: Mensah, V, وآخرون
منشور في: (2017)

DEVELOPING A NEW TB VACCINE: BOOSTING BCG WITH MVA85A
حسب: Mcshane, H
منشور في: (2008)

Two doses of candidate TB vaccine MVA85A in antiretroviral therapy (ART) naive subjects gives comparable immunogenicity to one dose in ART+ subjects
حسب: Dieye, T, وآخرون
منشور في: (2013)

Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa.
حسب: Hawkridge, T, وآخرون
منشور في: (2008)

Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: A phase 1, double-blind, randomised controlled trial
حسب: Satti, I, وآخرون
منشور في: (2014)

Correction: Safety and Immunogenicity of the Candidate Tuberculosis Vaccine MVA85A in West Africa
منشور في: (2011-01-01)

Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults: a phase I clinical trial.
حسب: Rowland, R, وآخرون
منشور في: (2013)

Effects of MVA85A vaccine on tuberculosis challenge in animals: systematic review
حسب: Mcshane, H, وآخرون
منشور في: (2016)

A Phase I study evaluating the safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV-infected adults
حسب: Minassian, A, وآخرون
منشور في: (2011)

Dose-finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG-vaccinated infants.
حسب: Scriba, T, وآخرون
منشور في: (2011)

The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial
حسب: Wajja, A, وآخرون
منشور في: (2017)

The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial.
حسب: Anne Wajja, وآخرون
منشور في: (2017-05-01)

Two doses of candidate TB vaccine MVA85A in antiretroviral therapy (ART) naïve subjects gives comparable immunogenicity to one dose in ART+ subjects.
حسب: Tandakha N Dieye, وآخرون
منشور في: (2013-01-01)

Improved adjuvanting of seasonal influenza vaccines: preclinical studies of MVA-NP+M1 coadministration with inactivated influenza vaccine.
حسب: Mullarkey, C, وآخرون
منشور في: (2013)

Evaluating aerosol administration of a candidate TB vaccine MVA85A
حسب: Thomas, Z, وآخرون
منشور في: (2014)

Correction: Two Doses of Candidate TB Vaccine MVA85A in Antiretroviral Therapy (ART) Naïve Subjects Gives Comparable Immunogenicity to One Dose in ART+ Subjects.
حسب: Tandakha N. Dieye, وآخرون
منشور في: (2013-01-01)

Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial.
حسب: Satti, I, وآخرون
منشور في: (2014)

Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials.
حسب: Mcshane, H, وآخرون
منشور في: (2005)

A first-in-human phase 1 trial to evaluate the safety and immunogenicity of the candidate tuberculosis vaccine MVA85A-IMX313, administered to BCG-vaccinated adults.
حسب: Minhinnick, A, وآخرون
منشور في: (2016)

The candidate TB vaccine, MVA85A, induces highly durable Th1 responses
حسب: Tameris, M, وآخرون
منشور في: (2014)

Th1/Th17 cell induction and corresponding reduction in ATP consumption following vaccination with the novel Mycobacterium tuberculosis vaccine MVA85A.
حسب: Griffiths, K, وآخرون
منشور في: (2011)